» Articles » PMID: 34819635

A Neuropsychosocial Signature Predicts Longitudinal Symptom Changes in Women with Irritable Bowel Syndrome

Overview
Journal Mol Psychiatry
Date 2021 Nov 25
PMID 34819635
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Irritable bowel syndrome (IBS) is a common disorder of brain-gut interactions characterized by chronic abdominal pain, altered bowel movements, often accompanied by somatic and psychiatric comorbidities. We aimed to test the hypothesis that a baseline phenotype composed of multi-modal neuroimaging and clinical features predicts clinical improvement on the IBS Symptom Severity Scale (IBS-SSS) at 3 and 12 months without any targeted intervention. Female participants (N = 60) were identified as "improvers" (50-point decrease on IBS-SSS from baseline) or "non-improvers." Data integration analysis using latent components (DIABLO) was applied to a training and test dataset to determine whether a limited number of sets of multiple correlated baseline'omics data types, including brain morphometry, anatomical connectivity, resting-state functional connectivity, and clinical features could accurately predict improver status. The derived predictive models predicted improvement status at 3-months and 12-months with 91% and 83% accuracy, respectively. Across both time points, non-improvers were classified as having greater correlated morphometry, anatomical connectivity and resting-state functional connectivity characteristics within salience and sensorimotor networks associated with greater pain unpleasantness, but lower default mode network integrity and connectivity. This suggests that non-improvers have a greater engagement of attentional systems to perseverate on painful visceral stimuli, predicting IBS exacerbation. The ability of baseline multimodal brain-clinical signatures to predict symptom trajectories may have implications in guiding integrative treatment in the age of precision medicine, such as treatments targeted at changing attentional systems such as mindfulness or cognitive behavioral therapy.

Citing Articles

Brain Morphometry and Cognitive Features in the Prediction of Irritable Bowel Syndrome.

Lundervold A, Bjorsvik B, Billing J, Berentsen B, Lied G, Steinsvik E Diagnostics (Basel). 2025; 15(4).

PMID: 40002622 PMC: 11854466. DOI: 10.3390/diagnostics15040470.


Aberrant functional connectivity patterns in the pregenual anterior cingulate cortex and anterior midcingulate cortex of patients with irritable bowel syndrome accompanied by depressive symptoms.

Tang R, Jin Y, Xu K, Wu L, Chen X, Guo Y Brain Imaging Behav. 2025; .

PMID: 39775692 DOI: 10.1007/s11682-024-00964-w.


Disease-specific alterations in central fear network engagement during acquisition and extinction of conditioned interoceptive fear in inflammatory bowel disease.

Lanters L, Ohlmann H, Langhorst J, Theysohn N, Engler H, Icenhour A Mol Psychiatry. 2024; 29(11):3527-3536.

PMID: 38802508 PMC: 11541002. DOI: 10.1038/s41380-024-02612-7.


Functional changes of default mode network and structural alterations of gray matter in patients with irritable bowel syndrome: a meta-analysis of whole-brain studies.

Zhao M, Hao Z, Li M, Xi H, Hu S, Wen J Front Neurosci. 2023; 17:1236069.

PMID: 37942144 PMC: 10627928. DOI: 10.3389/fnins.2023.1236069.


Clinical-functional brain connectivity signature predicts longitudinal symptom improvement after acupuncture treatment in patients with functional dyspepsia.

Yin T, Qu Y, Mao Y, Zhang P, Ma P, He Z Hum Brain Mapp. 2023; 44(16):5416-5428.

PMID: 37584456 PMC: 10543106. DOI: 10.1002/hbm.26449.


References
1.
Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

2.
Gralnek I, Hays R, Kilbourne A, Naliboff B, Mayer E . The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000; 119(3):654-60. DOI: 10.1053/gast.2000.16484. View

3.
Khan S, Chang L . Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010; 7(10):565-81. DOI: 10.1038/nrgastro.2010.137. View

4.
Niculescu A, Le-Niculescu H, Levey D, Roseberry K, Soe K, Rogers J . Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019; 24(4):501-522. PMC: 6477790. DOI: 10.1038/s41380-018-0345-5. View

5.
Wang X, Camilleri M . Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. World J Gastroenterol. 2019; 25(10):1185-1196. PMC: 6421234. DOI: 10.3748/wjg.v25.i10.1185. View